LUNG SQUAMOUS CELL CARCINOMA
Clinical trials for LUNG SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LUNG SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LUNG SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a new drug combo shrink tough lung tumors?
Disease control OngoingThis study tests whether adding the drug veliparib to standard chemotherapy and radiation helps people with stage III lung cancer that can't be removed by surgery. About 53 adults took part to find the best dose and see if the combination slows cancer growth. The goal is to impro…
Matched conditions: LUNG SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New cocktail for tough lung cancer shows promise in small trial
Disease control OngoingThis phase 2 pilot trial tested adding the drug bevacizumab to standard chemotherapy and radiation for patients with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 29 newly diagnosed patients to see if the combination is safe and helps …
Matched conditions: LUNG SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can AI be a Pathologist's second opinion?
Diagnosis ENROLLING_BY_INVITATIONThis trial tests whether an AI tool called ENLIGHT can help pathologists more accurately and quickly distinguish between certain lung and kidney cancer subtypes. Pathologists will review digitized slides under three conditions: without AI, with AI as a double-check after their ow…
Matched conditions: LUNG SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Harvard Medical School (HMS and HSDM) • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Can we predict who will benefit from immunotherapy? new study aims to find out.
Knowledge-focused OngoingThis study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …
Matched conditions: LUNG SQUAMOUS CELL CARCINOMA
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC